Skip to content

Study · Case report or series · n = 1 · 2020

1 result

Liraglutide-Induced Hemorrhagic Pancreatitis in a Nondiabetic Patient.

Dolan RD, Bazarbashi AN, Lo A, Smith BN

ACG case reports journal6 May 2020Cited by 8 (Europe PMC)

PMID32607380 (opens in a new tab)PMCIDPMC7289281 (opens in a new tab)DOI10.14309/crj.0000000000000380 (opens in a new tab)PepBankPUB-32607380
Download PDFPubMedAsk about this study
Jump to 1 result

Summary

Liraglutide is a glucagon-like peptide 1 (GLP-1) analog with a primary effect of increased glucose-dependent insulin secretion and decreased gastric emptying. It serves as a feasible medical weight loss option because of the drug's effect of invoking satiety and lowering caloric intake. Despite emerging efficacy, the GLP-1 class has been associated with severe, although rare, adverse events, including pancreatitis. Previous investigations demonstrated the greatest association between GLP-1 agonist-associated pancreatitis in diabetic populations; however, liraglutide dosing is higher in weight loss formulations, placing the weight loss population at higher risk. We present a case of liraglutide-induced acute pancreatitis in a patient without diabetes.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study1

1 result from studies that gave the peptide. 1 result from people.

  1. 01HumanCase report or seriesSafety outcome

    In one patient without diabetes, liraglutide treatment was followed by acute hemorrhagic pancreatitis, reported as liraglutide-induced.

    In plain wordsIn one patient without diabetes, liraglutide was reported to have caused acute pancreatitis.

    Peptide
    Liraglutide
    Outcome
    IncreaseAcute pancreatitis
    Study

    n = 1

    Outcome group
    Adverse events · Gastrointestinal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    We present a case of liraglutide-induced acute pancreatitis in a patient without diabetes.
    1 context sentence
    Title · context
    Liraglutide-Induced Hemorrhagic Pancreatitis in a Nondiabetic Patient.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 11:11 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.